The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.

Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG

Metabolism: clinical and experimental1 May 2002Cited by 90 (Europe PMC)

PMID11979398DOI10.1053/meta.2002.32022PepBankPUB-11979398

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialMechanism
In type 1 diabetes, intravenous pramlintide at 25 microg/h prevented the meal-related glucagon rise seen with placebo plus insulin.
In plain wordsIn type 1 diabetes, lower-dose intravenous pramlintide prevented the glucagon rise after meals seen with placebo plus insulin.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucagon rise
Study
n = 18
Comparator
Placebo plus insulin
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
25 microg/h · intravenous · 5-hour infusion in a 2-day studyAs given in this study (human).
Source sentences
Summary
In both studies plasma glucagon concentrations increased in response to the meal in the placebo-plus-insulin group but not in any of the pramlintide-treated groups (all pramlintide treatment arms v placebo, P <.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a 2-day crossover study, 18 patients received a 5-hour intravenous infusion of pramlintide (25 microg/h or 50 microg/h) or placebo in addition to subcutaneous (SC) insulin injections.
Summary · context
Plasma glucagon and glucose concentrations were measured before and after a standardized liquid meal in 2 separate randomized, double-blind, placebo-controlled studies of pramlintide administration to patients with type 1 diabetes.
Report a problemFND-1197939801
02HumanRandomized controlled trialMechanism
In type 1 diabetes, intravenous pramlintide at 50 microg/h prevented the meal-related glucagon rise seen with placebo plus insulin.
In plain wordsIn type 1 diabetes, higher-dose intravenous pramlintide prevented the glucagon rise after meals seen with placebo plus insulin.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucagon rise
Study
n = 18
Comparator
Placebo plus insulin
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
50 microg/h · intravenous · 5-hour infusion in a 2-day studyAs given in this study (human).
Source sentences
Summary
In both studies plasma glucagon concentrations increased in response to the meal in the placebo-plus-insulin group but not in any of the pramlintide-treated groups (all pramlintide treatment arms v placebo, P <.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a 2-day crossover study, 18 patients received a 5-hour intravenous infusion of pramlintide (25 microg/h or 50 microg/h) or placebo in addition to subcutaneous (SC) insulin injections.
Summary · context
Plasma glucagon and glucose concentrations were measured before and after a standardized liquid meal in 2 separate randomized, double-blind, placebo-controlled studies of pramlintide administration to patients with type 1 diabetes.
Report a problemFND-1197939802
03HumanRandomized controlled trialMechanism
In type 1 diabetes, subcutaneous pramlintide at 30 microg prevented the meal-related glucagon rise seen with placebo plus insulin.
In plain wordsIn type 1 diabetes, low-dose injected pramlintide prevented the glucagon rise after meals seen with placebo plus insulin.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucagon rise
Study
n: not reported in source
Comparator
Placebo plus insulin
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
30 microg 3 times daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
In both studies plasma glucagon concentrations increased in response to the meal in the placebo-plus-insulin group but not in any of the pramlintide-treated groups (all pramlintide treatment arms v placebo, P <.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a 14-day parallel-group study, 84 patients received SC injections of 30, 100, or 300 microg of pramlintide or placebo 3 times daily in addition to SC injections of insulin.
Summary · context
Plasma glucagon and glucose concentrations were measured before and after a standardized liquid meal in 2 separate randomized, double-blind, placebo-controlled studies of pramlintide administration to patients with type 1 diabetes.
Report a problemFND-1197939803
04HumanRandomized controlled trialMechanism
In type 1 diabetes, subcutaneous pramlintide at 100 microg prevented the meal-related glucagon rise seen with placebo plus insulin.
In plain wordsIn type 1 diabetes, intermediate-dose injected pramlintide prevented the glucagon rise after meals seen with placebo plus insulin.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucagon rise
Study
n: not reported in source
Comparator
Placebo plus insulin
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
100 microg 3 times daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
In both studies plasma glucagon concentrations increased in response to the meal in the placebo-plus-insulin group but not in any of the pramlintide-treated groups (all pramlintide treatment arms v placebo, P <.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a 14-day parallel-group study, 84 patients received SC injections of 30, 100, or 300 microg of pramlintide or placebo 3 times daily in addition to SC injections of insulin.
Summary · context
Plasma glucagon and glucose concentrations were measured before and after a standardized liquid meal in 2 separate randomized, double-blind, placebo-controlled studies of pramlintide administration to patients with type 1 diabetes.
Report a problemFND-1197939804
05HumanRandomized controlled trialMechanism
In type 1 diabetes, subcutaneous pramlintide at 300 microg prevented the meal-related glucagon rise seen with placebo plus insulin.
In plain wordsIn type 1 diabetes, high-dose injected pramlintide prevented the glucagon rise after meals seen with placebo plus insulin.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucagon rise
Study
n: not reported in source
Comparator
Placebo plus insulin
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
300 microg 3 times daily · subcutaneous · 14 daysAs given in this study (human).
Source sentences
Summary
In both studies plasma glucagon concentrations increased in response to the meal in the placebo-plus-insulin group but not in any of the pramlintide-treated groups (all pramlintide treatment arms v placebo, P <.05).
2 context sentences(design, population, supporting numbers)
Summary · context
In a 14-day parallel-group study, 84 patients received SC injections of 30, 100, or 300 microg of pramlintide or placebo 3 times daily in addition to SC injections of insulin.
Summary · context
Plasma glucagon and glucose concentrations were measured before and after a standardized liquid meal in 2 separate randomized, double-blind, placebo-controlled studies of pramlintide administration to patients with type 1 diabetes.
Report a problemFND-1197939805

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.